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Islet cell transplantation is currently the only feasible long-term treatment option for patients with type 1 diabetes. However, the
majority of transplanted islets experience damage and apoptosis during the isolation process, a blood-mediated inﬂammatory
microenvironment in the portal vein upon islet infusion, hypoxia induced by the low oxygenated milieu, and poor-
revascularization-mediated lack of nutrients, and impaired hormone modulation in the local transplanted site. Strategies using
genetic modiﬁcation methods through overexpression or silencing of those proteins involved in promoting new formation of
blood vessels or inhibition of apoptosis may overcome these hurdles and improve islet engraftment outcomes.
1.Introduction
Islet cell transplantation has been recognized as a treatment
option for Type 1 diabetes (T1D) after the introduction of
the Edmonton protocol that emphasizes the requirement
for both an adequate amount of donor islets and the use
of steroid-free immunosuppressive regimens [1]. However,
internationaltrialsconductedaroundtheworlddemonstrate
a constant decline of graft function and a relatively low rate
of successful engraftment compared with other solid organ
transplantations [2–5].
Islet cell transplantation has a much poorer success
rate than whole pancreas transplantation despite the same
degree of mismatched major histocompatibility complex
(MHC) alleles and similar immunosuppressive treatment
protocols in both types of pancreatic transplantation. The
pancreassurvival(insulin-independent)rateforwholeorgan
transplantation was 90%, 67%, and 36% at 1, 5, and 15
years respectively, after transplantation [6]. By contrast, the
insulin independent survival rate for pancreatic islet cell
transplantation rate dropped sharply to 10% at 5-years
despite comparable success rates at one year in both types
of transplantation [7].
Several factors may explain the discrepancies between
successful long-term pancreas engraftment and the low rate
ofsuccessinislettransplantation.Thekeydiﬀerencebetween
the two approaches is the mode of blood supply reestab-
lishment. Similar to other solid organ transplantations, the
transplanted pancreas can receive immediate blood supply
via physical reconnection of arterial and venous vessels. By
contrast, islets are avascular for several days following trans-
plantation, and blood ﬂow to transplanted islets is generated
through angiogenesis and/or vasculogenesis thereafter [8–
11].
Reconnection of blood supply is not only slower for
islet cells, but also inferior compared with whole pancreas
transplants. Data indicate that transplanted islets are less
vascularizedandhavealoweroxygentensionthanna¨ ıveislets
before isolation; even after revascularization is complete [8–
11]. As such, up to 70% of transplanted beta cells’ mass
may be destroyed in the early islet posttransplant period
in both immunodeﬁcient and syngeneic transplantation
models, suggesting a critical role of nonimmune factors in
determining the outcome of islet transplantation [12, 13].
Therefore, it is very important to address the nonimmune
aspects as well as allo- and/or auto-immune-mediated graft2 Journal of Transplantation
loss in islet transplantation to maximize the usage of limited
donor resources.
One of the fundamental requirements for successful
islet cell transplantation is the infusion of suﬃciently large
quantities of islets. Although it only requires as low as
20% of the islets within a pancreas to normalize the hyper-
glycemic state in diabetic cohorts, there are signiﬁcant
challenges to achieve satisfactory clinical outcomes in terms
of insulin independence. Key adverse factors that limit
successful islet transplantation include tissue damage and
cell apoptosis induced during the islet isolation process,
acute blood-mediated inﬂammatory injury of islets injected
into the portal vein, and extreme cytotoxicity to beta cells
due to high concentration of immunosuppressant drugs
accumulatedinthetransplantedsiteinadditiontotheabove-
mentioned hypoxia and prolonged oxidative stress caused by
slow and/or poor revascularization. Addressing these issues
will be instrumental for improving successful rates of islet
engraftment in clinical islet cell transplantation [8, 14–19].
The strategies for improving islet engraftment could be
achieved in several ways based on their origins. One of the
required procedures for islet transplantation is the isolation
of donor pancreas into individual islet cells. This step
potentiallyallowsforgeneticmodiﬁcation exvivoto improve
the survival of isolated islets, to increase the beta mass, and
to speed the process of new blood vessel reestablishment
for supply of oxygen and nutrients. In this review, we will
highlight the aspects of improving islet survival via gene
overexpression or deletion to minimize apoptosis during
isolation, to promote angiogenesis for revascularization, and
to avoid blood-mediated inﬂammatory responses.
2. Structure and Function of
Islets of Langerhans
Islets or islets of Langerhans are vascularized clusters of
cells within the pancreas that contain the insulin-producing
β cells. They were named after Paul Langerhans who
discovered islets in 1869 [4] .T h e r ea r eﬁ v et y p e so fc e l l s
within an islet, α, β, δ,p p ,a n dε cells that secrete hormones
of glucagon, insulin, somatostatin, pancreatic polypeptide,
and ghrelin, respectively. These cells reside in groups that
Langerhans likened to small islands in the pancreas and
release diﬀerent hormones into the portal vein in response
to changes in blood nutrient levels (Figure 1). Destruction of
insulin producing β cell by autoreactive T cells causes type 1
diabetes. Restoration of β-cell mass by islet transplantation
into the liver through the portal vein is considered to follow
the physiological route for hormone release.
The average weight of a human pancreas is 68g. The size
of an islet ranges from 50 to 250μM, with a mean diameter
of 140μM. The average numbers of islets for normal humans
are approximately 1 million, with a total beta-cell mass of
500 to 1500mg. The islets of Langerhans constitute 1-2% of
pancreas mass. However, they receive 10–20% of pancreatic
arteriolar ﬂow, demonstrating a signiﬁcant need for oxygen
and nutrients for immediate insulin secretion in response to
glucose stimulation [20, 21].
The distribution and percentage of individual cell types
in the islet are species-speciﬁc. Insulin expressing β cells are
the most abundant in all species, but the proportion and
localization are not the same [20, 21]. The percentage of
insulin positive cells is lower in human (55%) than in mouse
islets (77%). Those insulin-containing cells are located in
the core of each mouse islet. On the contrary, in human
islets, they are intermingled with other types of cells. The
glucagon secreting α cells are fewer (20%) compared with
β cells and located in the periphery of the mouse islets. By
contrast, they are only slightly lower in number than β cells
(40%) and scattered throughout the human islets. These
discrepancies result in a higher β/α cell ratio in mice and β
cells form the inner core of the mouse islets as compared
to humans. In the human pancreas, the other cell types are
located predominately in the periphery with the exception of
somatostatin-positive cells that are present throughout the
islet [21].
Despite the distinct cytoarchitecture and composition
of diﬀerent cell types cross-species, all cell types reside
close to islet blood vessels; no portion of an islet is more
than one cell away from arterial blood [9]. Approximately
86% of the α cells and 77% of the β cells are closely
apposed to vascular endothelial and smooth muscle cells
[21]. Although the diﬀerent cell types are aligned along
the vessels with no particular order, most β cells face
α and δ cells across the blood vessel lumen [21]. The
strategies for an islet to survive and fulﬁll its function
include enough contact with the blood vessels and structural
permeability to ensure suﬃcient ﬂow of arterial blood
into each individual islet (Figure 1). Arterioles enter islets
and form fenestrated microcirculation networks similar to
renal glomerular-like structures to allow for bidirectional
endocrine exchange and blood for nutrients and oxygen
[9]. An islet develops an intensive network of capillaries
with a thin collagen capsule and glial sheet that separates
the endocrine from the exocrine pancreas. In order to
regulate hormone secretion and function, islets are also
abundantly innervated by sympathetic and parasympathetic
nerves.
This complex structural arrangement is thought to
maintain glucose homeostasis through providing enough
supply of oxygen and nutrients to the islet cells, to enable
their metabolic sensing, and to allow the rapid distri-
bution of secreted hormones to target organs. However,
this perfect association is severely disrupted after pan-
creatic islets are isolated for transplantation. The essen-
tial nutrients and oxygen for islet survival and normal
function can only be supplied through diﬀusion from the
surrounding tissue into the transplanted islets following
transplantation. A new islet vascular system can be formed
within 7–14d [10, 11, 22]. However, the regenerated
islet vascular network is not the same as that observed
in islets before transplantation. In mice, the regenerated
network is only one third of that seen in na¨ ıve islets,
even when revascularization is complete [23]. Similarly,
engraftment is low when human islets are transplanted to
nude mice intraportally to the liver or at the renal site








Figure 1: Structure of the pancreas. Pancreas tissue consists of both exocrine and endocrine glands. Islets of Langerhans mainly include α-,
β-, and δ-cells. The islets are arranged in clusters associated with a dense network of capillaries. Most islet cells are directly in contact with
blood vessels.
3. Interventionsto Improve Graft
Vascular Function
The majority of transplanted islets are lost during the early
stages of transplantation; only approximately 20 to 30% of
donor islets are stably engrafted [22–24]. The reasons are
partially due to the disconnection of blood supply during
islet isolation and the slow/poor revascularization process
after islet transplantation. Therefore, islet engraftment rates
might be improved if interventional strategies for promoting
newly formed blood vessels are employed.
The growth of new blood vessels from preexisting
vessels or so called angiogenesis is a multiple-step event
that includes pericellular proteolysis, sprouting or migra-
tion/proliferationofendothelialcells(EC),formationofnew
capillaries, and maturation of blood vessels. The sequence
of molecular events for angiogenesis in islet transplantation
is largely unknown. However, it has been shown that
recruitment of angioblasts and overexpression of vascular
endothelial growth factor (VEGF) in the isolated islets can
promote angiogenesis and improve islet graft function [25–
27]. Three key families of angiogenic factor receptor tyrosine
kinases,theVEGFreceptors,Tiereceptors,andEphreceptors
playmajorrolesinregulatingtheprocessofangiogenesis[28,
29]. VEGF is a key regulator of physiological angiogenesis
during embryogenesis, skeletal growth, and reproductive
f u n c t i o n s .T h ea b s o l u t er e q u i r e m e n tf o rV E G Fi nb l o o d
vessel development is well established in mice. Mice with
single VEGF allele mutation die before birth as a result
of abnormal blood vessel formation, demonstrating strict
dependence on VEGF during development [30, 31].
VEGF-A is secreted by β-cells and plays a critical role
in regulating islet vascularization and function. It is also a
major regulator for interaction between β- and endothelial-
cells [32–34]. Several lines of evidence support this notion.
First,β-cell-speciﬁcinactivationofVEGF-Ainmousestudies
leads to reduced islet blood vessel density and size without
aﬀecting the exocrine vascular system. The substantial loss
of islet vessels, density, size, and permeability causes less
blood ﬂow into the mutants’ islets. Therefore, these mice
have impaired glucose-stimulated insulin secretion (GSIS)
resulting from decreased overall ﬂux of the stimuli into
the islets and a lower/delayed β-cell response following β-
cell exocytosis [32–34]. Further investigation revealed that
insulin deﬁciency is not a result of β-cell dysfunction, but
rather it is caused by abnormalities in islet vasculature. In
summary, mice deﬁcient for VEGF-A in pancreatic islets
exhibit abnormal phenotypes of both reduced vasculature
and impaired glucose tolerance.
VEGF-A is also required for vascularization of trans-
planted islets, but the process of isolation and transplan-
tation results in reduced expression of VEGF-A [27, 28].
Overexpression of VEGF-A via adenoviral transduction in
isolated islets, or endogenous expression in transgenic mice,
resultsinsuperiortransplantationoutcomes[27,28].VEGF-
A is normally expressed in islets in situ but expression
levels decrease 2-3 days after transplantation [27, 28]. Islets
deﬁcient in VEGF-A exhibit ineﬃcient revascularization
after transplantation into normal hosts and extensive islet
cell death immediately after transplantation [32–34]. Both
host blood vessels and residue donor islet endothelial cells
participate in the formation of a new islet vascular network
for graft vessel formation [22, 35, 36]. Reduced expression
of VEGF-A results in not only decreased numbers of
intraislet endothelial cells in donor islets, but also inadequate
recruitment of host endothelial cells and their migration
into the grafts [32–34]. Loss or gain of function by genetic
manipulation shows that VEGF-A is not only essential for
signiﬁcant angiogenic capacity, but also necessary for vascu-
larization. Endogenous expression VEGF-A from transgenic
mice under the control of a rat insulin promoter, or transient
overexpressionviaadenoviraldelivery,signiﬁcantlyenhances
microvasculardensity,functionalbloodﬂowtothegraft,and
long-term survival of functional islet mass [26, 27].
Under normal physiological conditions, vasculature
and/or endothelial cells proliferate at a very low rate.
This quiescence is thought to be maintained by the bal-
ance between proangiogenic (also called stimulators) and
antiangiogenic factors (inhibitors). Therefore, strategies for
promoting new blood vessel formation include both overex-
pression of stimulators and deletion of inhibitors (Figure 2).
Thrombospondin-1 (TSP-1) is an inhibitor of angiogenesis
[37–40]. Its antiangiogenic function is through the regula-
tion of extracellular matrix function, blood clot formation,4 Journal of Transplantation
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Figure 2: Factors controlling successful islet engraftment. The
successful engraftment of transplanted islets is determined by
both the ability to form new blood vessels and the capacity to
limit apoptosis induced by both extrinsic (induced by extracellular
inducers, such as inﬂammatory cytokines) and intrinsic (induced
by intrinsic factors, such as hypoxia and nutrient deprivation)
pathways. Proangiogenic factors such as VEGF, Ang-1, and ephrin
promote angiogenesis. By contrast, antiangiogenic factors such as
TSP-1 reduce this process.
and immune responses [37–40]. The unique feature of
inhibitory regulation by TSP-1 is its selective induction of
apoptosis on activated, but not quiescent, endothelial cells
through binding to their extracellular matrix, suggesting
a highly selective target to newly forming blood vessels
without disturbing other nondividing endothelial cells [37].
In addition, it also functions as an antagonist of angiogenesis
by preventing the recruitment of proangiogenic factors,
such as matrix metalloproteinase-9 and VEGF, to the site
for new blood-vessel formation, and blocking the binding
to their counter-receptors on the endothelial cells [41]. In
concordance with this function, TSP-1 knockout mice have
hypervascularized islets [37]. Islets made deﬁcient in TSP-
1, through knockout gene expression or RNA silencing,
display an increased vascular density when compared with
control islets 1 month after transplantation [42]. However,
subsequent studies revealed that TSP-1 is important for β
cell function [43]. Mice deﬁcient in TSP-1 show glucose
intolerance, impaired insulin biosynthesis, and glucose oxi-
dation rate. TSP-1 deﬁcient mice treated with transforming
growth factor (TGF) β-1-activating sequences recover their
normal capacity of glucose tolerance, suggesting that TSP-1
functions via the TGFβ-1 pathway [43]. Deletion of antian-
giogenic factor TSP-1 promotes islet engraftment through
creating a microenvironment for blood vessel growth, blood
perfusion and oxygenation in the graft, therefore, improving
islet graft revascularization and function.
4. Strategies to Prevent β-CellApoptosis
Apoptosis induced in the transplanted islets arises from the
isolation process, a blood-mediated inﬂammatory reaction
upon injection, immunosuppressive drug-related direct tox-
icity to β-cell function, and hypoxia/oxidative stress during
the revascularization process [4, 5, 16].
Programmed cell death or apoptosis can be regulated
through two distinct pathways, namely, the extrinsic and
intrinsic pathways (Figure 2). In the extrinsic pathway, extra-
cellular events, such as the release of inﬂammatory cytokines
during the disassociation and isolation of donor islets via
collagenase/protease digestion, can initiate β-cell apoptosis.
Proapoptotic cytokines and other signaling molecules acti-
vate apoptosis initiator caspase 8, leading to eﬀector caspase
activation,andpromotingcleavageofprocaspasetoactivated
caspase 3. Intracellular or intrinsic inducers, such as hypoxia
and nutrient deprivation due to disconnection of the blood
supply during donor islet isolation and the revascularization
process, activate the mitochondrial pathway. This pathway is
regulatedbythebalancebetweenproapoptoticproteins,such
as Bax and Bad, and anti-apoptotic proteins, such as Bcl-2
and Bcl-XL. The release of cytochrome c from mitochondria
to the cell cytosol stimulates the activation of apoptosis
initiator caspase 9, which then activates eﬀector caspase 3.
Strategies for preventing β-cell apoptosis are considered in
three diﬀerent ways: blocking the inducers, modulating key
proteins in each pathway, or inhibiting eﬀector caspases at
the ﬁnal stages [44].
The inhibitor of apoptosis protein (IAP) family includes
a number of endogenous antiapoptotic genes, including X-
linkedIAP(XIAP).XIAPisthemostpotentcaspaseinhibitor
in the IAP family and functions to restrain apoptotic cell
death by preventing activation of initiator caspase 9, as
well as eﬀector caspases 3 and 7, through binding to the
active site of those caspases. Overexpression of XIAP in
donorisletsdramaticallyreducesthenumberofhumanislets
required to reverse hyperglycemia in chemically diabetic
immunodeﬁcient mice [45]. It also reverses the adverse
eﬀects of immunosuppressive drugs on insulin secretion and
enhances cell viability of isolated human islets [46].
Another apoptosis inhibitor also shows beneﬁcial eﬀects
on preventing β-cell apoptosis. Treatment with Val-Pro-
Met-Leu-Lys (V5), a cell-permeable apoptosis inhibitor
pentapeptide, improves the donor islet mass following
collagenase digestion and isolation [47]. This treatment also
reduces the number of donor islets required for reverse
hyperglycemia in streptozotocin-induced diabetic mice. The
mechanism for this action is through upregulating anti-
apoptotic proteins Bcl-2 and XIAP as well as downregu-
lating Proapoptotic proteins Bax and Bad. These studies
indicate that the inhibition of apoptosis by overexpression
of anti-apoptotic proteins directly or indirectly signiﬁcantly
improvesisletfunctionfollowingisolationandimprovesislet
graft function post transplant.
β cells are known to be sensitive to apoptosis. Several
mediators have been found to cause dysfunction and/or
cellular death of the pancreatic islets including inﬂammatory
cytokines such as interleukin 1 β (IL-1β), TNF-α,a n dI F N - γ,
which in turn promote the release of inducible nitric oxide
synthase (iNOS) and cytotoxic nitric oxide (NO) [48–51].
In fact, the production of iNOS and NO is signiﬁcantly
elevated after transplantation [51]. Blocking of iNOS via
small interfering RNA (siRNA) decreases iNOS expression,
NO production, and iNOS/NO-mediated apoptosis [52].
Inﬂammatory cytokines are also known to be upregulatedJournal of Transplantation 5
due to the oxidative stress induced during isolation and
nutrient deprivation after transplantation [51]. More impor-
tantly, systemic administration of IL-1 receptor antagonist
protein subcutaneously or local delivery via adenovirus
prevents IL-1β-induced β-cell impairment/apoptosis in vitro
and prolongs mouse islet allograft survival in vivo [49, 50].
The numbers of donor islets required for transplantation
couldbereducedusingreagentsthatblockapoptosisthrough
inhibiting proinﬂammatory cytokines, or modulating the
proteins participating in the extrinsic and/or intrinsic apop-
tosis pathways. Islet engraftment improvement might also be
achieved through increasing β- c e l lm a s s[ 53, 54]. Adenoviral
delivery of hepatocyte growth factor (HGF) to nonhuman
primate islets improves graft survival and function in
streptozotocin-induced diabetic NOD-SCID mice, markedly
reducing the number of islets required to achieve normal
glucose control. The delivery method for up- or down-
regulation of the genes to improve islet engraftment has been
limited to mostly replication-deﬁcient adenoviral systems
due to the nondividing feature of the islet cells. Several
studies have explored the nonviral vector for application in
clinical islet transplantation [55, 56]. Both Eﬀectene and
polyethylenimine showed higher gene-delivery eﬃciency for
pancreatic islets compared with other classes of nonviral
delivery systems and are promising as gene delivery agents
for pretransplant ex vivo gene therapy of islets.
5. Conclusion
Islet cell transplantation itself is a great surgical procedure
for treating type 1 diabetes. However, it is largely impeded
by the limited number of islet donors. In order to achieve
insulinindependence,atleast10,000isletequivalents(IE)/kg
recipient body weight is needed [1–5]. In fact, signiﬁcantly
more islets must be transplanted to reverse hyperglycemia
because a considerably high number of donor islets are lost
due to the injuries from enzymatic/mechanical-mediated
damage during isolation, and lack of oxygen and nutrient
supply during the slow reestablishment of blood supply to
the transplanted islets. In another words, if this signiﬁcant
loss of donor islets canbe avoided, then more diabetic recipi-
entscanbetransplanted,and/orbetterinsulin-independence
rates will be achieved with the same number of currently
available donors. Interventional strategies to improve islet
engraftment by gene therapy could have a dramatic impact
on the number of patients that might beneﬁt from this
therapy and could aﬀect long-term graft survival.
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